EMA Authorised: Farydak (panobinostat lactate anhydrous) — pharmaand GmbH

View source ↗

Summary

The EMA authorised Farydak (panobinostat lactate anhydrous) for the treatment of multiple myeloma. The marketing authorization holder is pharmaand GmbH, with th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Farydak (panobinostat)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: pharmaand GmbH. Decision date: 28/11/2024